Concomitant palonosetron ameliorates cisplatin-induced nephrotoxicity, nausea, and vomiting: a retrospective cohort study and pharmacovigilance analysis

Table 3 Analyses on the effect of 5-HT₃RAs on CDDP-associated acute kidney failure in patients received with CDDP and triple antiemetic therapy using the JADER database

	CDDP-associated acute kidney injury (%)		ROR (95% CI)
	Without drug	With drugs	ROR (95% CI)
Granisetron	43/370 (12)	29/265 (11)	0.934 (0.567–1.540)
Ondansetron	69/609 (11)	3/26 (12)	1.021 (0.299–3.489)
Palonosetron	31/130 (24)	41/505 (8)	0.282 (0.169–0.472)
Ramosetron	72/599 (12)	0/36 (0)	0.100 (0.006–1.642)

Ratio of CDDP-associated acute kidney injury is presented as cases / (cases + non-cases) (%)
5-HT₃RA 5-hydroxytryptamine type 3 receptor antagonist, CI confidence interval, JADER Japanese Adverse Drug Event Report, ROR reporting odds ratio

ISSN: 2055-0294